StockData
Inhibitor Therapeutics, Inc. logo

Inhibitor Therapeutics, Inc. (INTI) bonds

INTIOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 1/30
$0.11+0.00 (+0.09%)

Close on Oct 19, 2026Market cap $19.06MP/E –Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Total debt
$47.83K
$26.26K due within a year
Net debt
-$467.93K
After $515.76K of cash
Implied interest rate
–
FY2025 interest ÷ average debt
Interest coverage
–
FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

When the debt comes due

Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2025

From the debt maturity table in the annual report (filing). “Later” is everything due after year five.

Notes and loans outstanding

As tagged in Inhibitor Therapeutics's 10-K for the period ended Dec 12, 2020

Inhibitor Therapeutics's filings do not break debt down by note

The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed. The repayment schedule above comes from the same report.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySizeAvailable
Mayne Pharma$231.00K$75.00K

See a number that looks wrong?